Meeting
2018 ASCO Annual Meeting
PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).
Authors
Jennifer Bordeaux
Navigate BioPharma Services, Inc, Carlsbad, CA
Jennifer Bordeaux , Naveen Dakappagari , Nathan A. Pennell , James Stevenson , Monica Khunger , Christine Vaupel , Kurt A. Schalper , David L. Rimm , Vamsidhar Velcheti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Immunobiology
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12059)
DOI
10.1200/JCO.2018.36.15_suppl.12059
Abstract #
12059
Poster Bd #
172
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).
First Author: Cecile Vicier
Poster
2022 ASCO Annual Meeting
Analysis of the contribution of macrophages to the overall tumor PD-L1 microenvironment using a screening multi-tumor tissue microarray and rapid multiplex fluorescence digital phenotyping approach.
First Author: Marie Cumberbatch
Poster
2022 ASCO Annual Meeting
Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study.
First Author: Felix Blanc-Durand
Poster
2022 ASCO Genitourinary Cancers Symposium
FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).
First Author: Elio Adib